Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Glucagon-like Peptide 1 Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The glucagon-like peptide 1 market has experienced substantial growth in recent years. It is projected to expand from $22.06 billion in 2025 to $23.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. The historical increase can be attributed to several factors, including the increasing prevalence of diabetes, rising global obesity rates, the growing acceptance of injectable peptide therapies, the expansion of endocrinology treatment options, and the availability of branded glp-1 drugs.
The glucagon-like peptide 1 market is set for significant expansion in the coming years. By 2030, its size is projected to reach $33.26 billion, driven by a compound annual growth rate (CAGR) of 8.6%. This growth throughout the forecast period stems from factors such as increasing demand for weight management therapies, rising investments in peptide drug innovation, the expansion of oral peptide delivery technologies, a growing focus on chronic disease management, and the increasing adoption of personalized medicine. Key trends during this period include the rising adoption of GLP-1 therapies for obesity management, increasing development of oral GLP-1 formulations, a growing focus on long-acting peptide drugs, the expansion of combination therapy approaches, and enhanced patient-centric drug delivery systems.
Get A Free Sample Report With In-Depth Market Insights:
Glucagon-like Peptide 1 Market Demand Drivers: What’s Powering Industry Growth?
The future expansion of the glucagon-like peptide 1 (GLP-1) market is anticipated to be fueled by a growing focus on personalized medicine. This approach to medication involves utilizing insights into an individual’s genetic makeup or proteins to prevent, identify, or address illnesses. Through personalized medicine, GLP-1 formulations and their dosages can be customized to suit the specific requirements and preferences of each patient. An illustrative example, cited in February 2024 by the Personalized Medicine Coalition, a US-based non-profit organization, highlights that in 2023, the FDA sanctioned 16 novel personalized treatments aimed at rare disease patients, marking an increase from six approvals in 2022. Among these newly approved personalized treatments for 2023 were also seven medications for cancer and three for various other diseases and conditions. Consequently, the heightened focus on personalized medicine is indeed stimulating the expansion of the glucagon-like peptide 1 (GLP-1) market.
Glucagon-like Peptide 1 Market Segment Breakdown: Which Categories Lead On Revenue?
The glucagon-like peptide 1 market covered in this report is segmented –
1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By End-Users: Hospitals, Specialty Clinics, Other End Users
Subsegments:
1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)
2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)
3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)
4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)
5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems
Glucagon-like Peptide 1 Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading companies in the glucagon-like peptide 1 market are concentrating on advancing technology to improve therapeutic efficacy, safety, and user convenience in both weight management and diabetes care. Glucagon-like peptide 1 (GLP-1) therapies are injectable, peptide-based medications that mimic the function of the natural GLP-1 hormone to regulate appetite, glucose metabolism, and body weight. As an illustration, in March 2024, Novo Nordisk A/S, a pharmaceutical company based in Denmark, introduced Wegovy, which is the first and only once-weekly GLP-1 therapy specifically for weight management. This therapy, which emerged from the STEP Phase 3a clinical trial program, exhibited a safe and well-tolerated profile and is intended to aid individuals with obesity in achieving and maintaining weight loss. By offering a convenient weekly dosing regimen, Wegovy boosts patient adherence and addresses the increasing need for innovative, effective treatments for obesity.
Glucagon-like Peptide 1 Market Leading Players And Competitive Positioning
Major companies operating in the glucagon-like peptide 1 market are Novo Nordisk, Eli Lilly And Company, Pfizer Inc., AstraZeneca Plc, Sanofi S.A., Boehringer Ingelheim International GmbH, Merck And Co., Inc., Takeda Pharmaceutical Company Limited, Roche Holding AG, Johnson And Johnson, Amgen Inc., GlaxoSmithKline Plc, Novartis AG, Bayer AG, AbbVie Inc., Bristol Myers Squibb Company, Biocon Limited, Hanmi Pharmaceutical Co., Ltd., Innovent Biologics, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Zealand Pharma A/S, Gan And Lee Pharmaceuticals Co., Ltd.
View The Full Glucagon-like Peptide 1 Market Report:
Glucagon-like Peptide 1 Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the glucagon-like peptide 1 market in 2025. The regions covered in the glucagon-like peptide 1 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.
